Literature DB >> 9029126

C5a-dependent up-regulation in vivo of lung vascular P-selectin.

M S Mulligan1, E Schmid, G O Till, T E Hugli, H P Friedl, R A Roth, P A Ward.   

Abstract

Acute lung injury in rats following systemic activation of complement by i.v. infusion of cobra venom factor (CVF) is known to be P-selectin dependent. In the current studies, infusion of CVF caused the appearance in plasma of C5a (as revealed by ELISA analysis) together with neutrophil chemotactic activity, which was totally blocked by addition in vitro of anti-rat C5a. Using a detector 125I-labeled antibody to rat P-selectin, we have demonstrated quantitative up-regulation in vivo of lung vascular P-selectin in a time-dependent manner after infusion of CVF. This up-regulation was almost completely blocked by prior complement depletion or by the infusion of anti-rat C5a. Platelet depletion did not affect CVF-induced up-regulation of lung vascular P-selectin, indicating that platelets were not the source of P-selectin. These results demonstrate that complement and, specifically, C5a are necessary for up-regulation of lung vascular P-selectin after systemic activation of complement.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029126

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Complement activation promotes muscle inflammation during modified muscle use.

Authors:  J Frenette; B Cai; J G Tidball
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement.

Authors:  B J Czermak; A B Lentsch; N M Bless; H Schmal; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

3.  The C5a receptor is expressed by human renal proximal tubular epithelial cells.

Authors:  R Zahedi; M Braun; R A Wetsel; B H Ault; A Khan; T R Welch; M Frenzke; A E Davis
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 4.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

5.  Differing patterns of P-selectin expression in lung injury.

Authors:  N M Bless; S J Tojo; H Kawarai; Y Natsume; A B Lentsch; V A Padgaonkar; B J Czermak; H Schmal; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

6.  Generation of C5a by phagocytic cells.

Authors:  Markus Huber-Lang; Ellen M Younkin; J Vidya Sarma; Niels Riedemann; Stephanie R McGuire; Kristina T Lu; Robin Kunkel; John G Younger; Firas S Zetoune; Peter A Ward
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

7.  Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin.

Authors:  Norman F Russkamp; Robert Ruemmler; Julian Roewe; Bethany B Moore; Peter A Ward; Markus Bosmann
Journal:  FASEB J       Date:  2015-05-21       Impact factor: 5.191

8.  Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma.

Authors:  Fei Qiao; Carl Atkinson; Hongbin Song; Ravinder Pannu; Inderjit Singh; Stephen Tomlinson
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

9.  Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells.

Authors:  Lei Sun; Ren-Feng Guo; Hongwei Gao; J Vidya Sarma; Firas S Zetoune; Peter A Ward
Journal:  FASEB J       Date:  2009-07-20       Impact factor: 5.191

10.  Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis.

Authors:  Michael A Flierl; Philip F Stahel; Daniel Rittirsch; Markus Huber-Lang; Andreas D Niederbichler; L Marco Hoesel; Basel M Touban; Steven J Morgan; Wade R Smith; Peter A Ward; Kyros Ipaktchi
Journal:  Crit Care       Date:  2009-02-06       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.